The utility of -synuclein as biofluid marker in
neurodegenerative diseases: a systematic review of the
literature

J 2016

The utility of -synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature

SIMONSEN, Anja Hviid; Bea KUIPERIJ; Omar Mukhtar Ali EL-AGNAF; Sebastian ENGELBORGHS; Sanna-Kaisa HERUKKA et al.

Základní údaje

Originální název

The utility of -synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature

Autoři

Vydání

BIOMARKERS IN MEDICINE, LONDON, FUTURE MEDICINE LTD, 2016, 1752-0363

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30000 3. Medical and Health Sciences

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.020

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14740/16:00089458

Organizační jednotka

Středoevropský technologický institut

Klíčová slova anglicky

alpha-synuclein; biomarker; CSF; diagnosis; ELISA; Parkinson's disease

Štítky

rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 4. 8. 2016 09:41, Mgr. Eva Špillingová

Anotace

V originále

The discovery of -synuclein (-syn) as a major component of Lewy bodies, neuropathological hallmark of Parkinson's disease (PD), dementia with Lewy bodies and of glial inclusions in multiple system atrophy initiated the investigation of -syn as a biomarker in cerebrospinal fluid (CSF). Due to the involvement of the periphery in PD the quantification of -syn in peripheral fluids such as serum, plasma and saliva has been investigated as well. We review how the development of multiple assays for the quantification of -syn has yielded novel insights into the variety of -syn species present in the different fluids; the optimal preanalytical conditions required for robust quantification and the potential clinical value of -syn as biomarker. We also suggest future approaches to use of CSF -syn in neurodegenerative diseases.

Návaznosti

ED1.1.00/02.0068, projekt VaV

Název: CEITEC - central european institute of technology

Přiložené soubory

ZVV_2015_144_1337320_The_utility.xlsx

Požádat o autorskou verzi souboru

ZVV_2016_004_1337320_The_utility.pdf

Požádat o autorskou verzi souboru

Citovat

SIMONSEN, Anja Hviid; Bea KUIPERIJ; Omar Mukhtar Ali EL-AGNAF; Sebastian ENGELBORGHS; Sanna-Kaisa HERUKKA; Lucilla PARNETTI; Irena REKTOROVÁ; Eugeen VANMECHELEN; Elisabeth KAPAKI; Marcel VERBEEK a Brit MOLLENHAUER. The utility of -synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. BIOMARKERS IN MEDICINE. LONDON: FUTURE MEDICINE LTD, 2016, roč. 10, č. 1, s. 19-34. ISSN 1752-0363. Dostupné z: https://doi.org/10.2217/BMM.14.105.

@article{1337320,
   author = {Simonsen, Anja Hviid and Kuiperij, Bea and ElandAgnaf, Omar Mukhtar Ali and Engelborghs, Sebastian and Herukka, SannaandKaisa and Parnetti, Lucilla and Rektorová, Irena and Vanmechelen, Eugeen and Kapaki, Elisabeth and Verbeek, Marcel and Mollenhauer, Brit},
   article_location = {LONDON},
   article_number = {1},
   doi = {https://doi.org/10.2217/BMM.14.105},
   keywords = {alpha-synuclein; biomarker; CSF; diagnosis; ELISA; Parkinson's disease},
   language = {eng},
   issn = {1752-0363},
   journal = {BIOMARKERS IN MEDICINE},
   title = {The utility of -synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature},
   url = {http://www.futuremedicine.com/doi/10.2217/BMM.14.105},
   volume = {10},
   year = {2016}
}

TY  - JOUR
ID  - 1337320
AU  - Simonsen, Anja Hviid - Kuiperij, Bea - El-Agnaf, Omar Mukhtar Ali - Engelborghs, Sebastian - Herukka, Sanna-Kaisa - Parnetti, Lucilla - Rektorová, Irena - Vanmechelen, Eugeen - Kapaki, Elisabeth - Verbeek, Marcel - Mollenhauer, Brit
PY  - 2016
TI  - The utility of -synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature
JF  - BIOMARKERS IN MEDICINE
VL  - 10
IS  - 1
SP  - 19-34
EP  - 19-34
PB  - FUTURE MEDICINE LTD
SN  - 17520363
KW  - alpha-synuclein
KW  - biomarker
KW  - CSF
KW  - diagnosis
KW  - ELISA
KW  - Parkinson's disease
UR  - http://www.futuremedicine.com/doi/10.2217/BMM.14.105
L2  - http://www.futuremedicine.com/doi/10.2217/BMM.14.105
N2  - The discovery of -synuclein (-syn) as a major component of Lewy bodies, neuropathological hallmark of Parkinson's disease (PD), dementia with Lewy bodies and of glial inclusions in multiple system atrophy initiated the investigation of -syn as a biomarker in cerebrospinal fluid (CSF). Due to the involvement of the periphery in PD the quantification of -syn in peripheral fluids such as serum, plasma and saliva has been investigated as well. We review how the development of multiple assays for the quantification of -syn has yielded novel insights into the variety of -syn species present in the different fluids; the optimal preanalytical conditions required for robust quantification and the potential clinical value of -syn as biomarker. We also suggest future approaches to use of CSF -syn in neurodegenerative diseases.
ER  -

SIMONSEN, Anja Hviid; Bea KUIPERIJ; Omar Mukhtar Ali EL-AGNAF; Sebastian ENGELBORGHS; Sanna-Kaisa HERUKKA; Lucilla PARNETTI; Irena REKTOROVÁ; Eugeen VANMECHELEN; Elisabeth KAPAKI; Marcel VERBEEK a Brit MOLLENHAUER. The utility of -synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. \textit{BIOMARKERS IN MEDICINE}. LONDON: FUTURE MEDICINE LTD, 2016, roč.~10, č.~1, s.~19-34. ISSN~1752-0363. Dostupné z: https://doi.org/10.2217/BMM.14.105.

Přehled o publikaci